Antimicrobial drug pricing
- PMID: 39394271
- PMCID: PMC11470128
- DOI: 10.1038/s43856-024-00594-9
Antimicrobial drug pricing
Abstract
Despite the constant development of antimicrobial resistance (AMR), few new antimicrobials are currently becoming available clinically. Alternative approaches, such as different mechanisms to fund their use, are being explored to encourage development of new antimicrobials.
© 2024. The Author(s).
Conflict of interest statement
The authors declare the following competing interests: BW sits on the board of directors for the York Health Economic Consortium, a health economics consulting company wholly owned by the University of York. This role is unpaid. C.L., T.R., H.T. and Z.R. are employees of Pfizer. T.A. is an elected member of BSAC council and leads a consultancy across the AMR sector for organisations which have recently included The Microbiology Society, The UK Sepsis Trust, The Infection Management Coalition, Menarini Pharmaceuticals, Binary Pharmaceuticals, ESSITY and Pharmafilter. T.A. is a committee member for the GARDP/BSAC Antimicrobial Chemotherapy Conference 2025. T.A. is a GMC registered physician and prescriber. M.A. is the Deputy Chief Executive Officer of the British Society for Antimicrobial Chemotherapy (BSAC). As part of this role, T.A. helps to provide the Secretariat for the UK’s All-Party Parliamentary Group on Antimicrobial Resistance (AMR). T.A. also sits on the Steering Committee of the Trinity Challenge and is a Trustee of the Charades Theatre Company I.B. reports investigator-initiated research funding from Shionogi B.V. for research on Gram-negative infections; honoraria from Shionogi B.V. and Menarini UK; participating in an advisory board for GSK on the UK subscription model for antimicrobials. The other authors declare no competing interests.
Figures
References
-
- DRUG-RESISTANT INFECTIONS A Threat to Our Economic Future. www.worldbank.org Published online 2017. (2024).
-
- WHO Model List of Essential Medicines − 23rd list, 2023. https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02 (2024).
-
- Compulsory Licensing in India and changes brought to it by the TRIPS Agreement - European Commission. https://intellectual-property-helpdesk.ec.europa.eu/news-events/news/com... (2024).
LinkOut - more resources
Full Text Sources